Literature DB >> 14701812

Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein.

Elda Favari1, Miriam Lee, Laura Calabresi, Guido Franceschini, Francesca Zimetti, Franco Bernini, Petri T Kovanen.   

Abstract

The ATP-binding cassette transporter A1 (ABCA1) mediates the efflux of cellular unesterified cholesterol and phospholipid to lipid-poor apolipoprotein A-I. Chymase, a protease secreted by mast cells, selectively cleaves pre-beta-migrating particles from high density lipoprotein (HDL)(3) and reduces the efflux of cholesterol from macrophages. To evaluate whether this effect is the result of reduction of ABCA1-dependent or -independent pathways of cholesterol efflux, in this study we examined the efflux of cholesterol to preparations of chymase-treated HDL(3) in two types of cell: 1) in J774 murine macrophages endogenously expressing low levels of scavenger receptor class B, type I (SR-BI), and high levels of ABCA1 upon treatment with cAMP; and 2) in Fu5AH rat hepatoma cells endogenously expressing high levels of the SR-BI and low levels of ABCA1. Treatment of HDL(3) with the human chymase resulted in rapid depletion of pre-beta-HDL and a concomitant decrease in the efflux of cholesterol and phospholipid (2-fold and 3-fold, respectively) from the ABCA1-expressing J774 cells. In contrast, efflux of free cholesterol from Fu5AH to chymase-treated and to untreated HDL(3) was similar. Incubation of HDL(3) with phospholipid transfer protein led to an increase in pre-beta-HDL contents as well as in ABCA1-mediated cholesterol efflux. A decreased cholesterol efflux to untreated HDL(3) but not to chymase-treated HDL(3) was observed in ABCA1-expressing J774 with probucol, an inhibitor of cholesterol efflux to lipid-poor apoA-I. Similar results were obtained using brefeldin and gliburide, two inhibitors of ABCA1-mediated efflux. These results indicate that chymase treatment of HDL(3) specifically impairs the ABCA1-dependent pathway without influencing either aqueous or SR-BI-facilitated diffusion and that this effect is caused by depletion of lipid-poor pre-beta-migrating particles in HDL(3). Our results are compatible with the view that HDL(3) promotes ABCA1-mediated lipid efflux entirely through its lipid-poor fraction with pre-beta mobility.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14701812     DOI: 10.1074/jbc.M312476200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

Review 1.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

2.  An integrated approach for the mechanisms responsible for atherosclerotic plaque regression.

Authors:  Andrew A Francis; Grant N Pierce
Journal:  Exp Clin Cardiol       Date:  2011

3.  ABCA1-dependent serum cholesterol efflux capacity inversely correlates with pulse wave velocity in healthy subjects.

Authors:  Elda Favari; Nicoletta Ronda; Maria Pia Adorni; Francesca Zimetti; Paolo Salvi; Matteo Manfredini; Franco Bernini; Claudio Borghi; Arrigo F G Cicero
Journal:  J Lipid Res       Date:  2012-10-28       Impact factor: 5.922

4.  Spontaneous remodeling of HDL particles at acidic pH enhances their capacity to induce cholesterol efflux from human macrophage foam cells.

Authors:  Su Duy Nguyen; Katariina Öörni; Miriam Lee-Rueckert; Tero Pihlajamaa; Jari Metso; Matti Jauhiainen; Petri T Kovanen
Journal:  J Lipid Res       Date:  2012-08-01       Impact factor: 5.922

5.  Enhanced cholesterol efflux to HDL through the ABCA1 transporter in hypertriglyceridemia of type 2 diabetes.

Authors:  Hussein N Yassine; Alexandra Belopolskaya; Christina Schall; Craig S Stump; Serrine S Lau; Peter D Reaven
Journal:  Metabolism       Date:  2014-03-05       Impact factor: 8.694

Review 6.  Emerging role of mast cells and macrophages in cardiovascular and metabolic diseases.

Authors:  Jia-Ming Xu; Guo-Ping Shi
Journal:  Endocr Rev       Date:  2012-01-12       Impact factor: 19.871

7.  Pharmaceutical stabilization of mast cells attenuates experimental atherogenesis in low-density lipoprotein receptor-deficient mice.

Authors:  Jing Wang; Sara Sjöberg; Viviane Tia; Blandine Secco; Han Chen; Min Yang; Galina K Sukhova; Guo-Ping Shi
Journal:  Atherosclerosis       Date:  2013-06-07       Impact factor: 5.162

8.  Regulation of Hepatic Cholesteryl Ester Transfer Protein Expression and Reverse Cholesterol Transport by Inhibition of DNA Topoisomerase II.

Authors:  Mengyang Liu; Yuanli Chen; Ling Zhang; Qixue Wang; Xingzhe Ma; Xiaoju Li; Rong Xiang; Yan Zhu; Shucun Qin; Yang Yu; Xian-cheng Jiang; Yajun Duan; Jihong Han
Journal:  J Biol Chem       Date:  2015-04-25       Impact factor: 5.157

9.  Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks.

Authors:  Xin-Min Li; Wai Hong Wilson Tang; Marian K Mosior; Ying Huang; Yuping Wu; William Matter; Vivian Gao; David Schmitt; Joseph A Didonato; Edward A Fisher; Jonathan D Smith; Stanley L Hazen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-03-21       Impact factor: 8.311

10.  The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages.

Authors:  Margarita de la Llera-Moya; Denise Drazul-Schrader; Bela F Asztalos; Marina Cuchel; Daniel J Rader; George H Rothblat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-01-14       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.